Literature DB >> 18246466

Intron F G79A polymorphism of the protein Z gene in cancer patients with and without thrombosis.

Aydan Eroglu1, Aysenur Ozturk, Ragip Cam, Nejat Akar.   

Abstract

BACKGROUND AND
PURPOSE: Venous thromboembolism (VTE) is well-recognized complication of cancer; however its pathogenesis is not entirely established. Protein Z (PZ) is a member of the coagulation cascade. We aimed to investigate whether intron F G79A polymorphism of PZ gene is associated with risk of VTE in cancer patients.
MATERIALS AND METHODS: The study consisted of 55 cancer patients who developed thrombosis (group 1) and 115 cancer patients without VTE (group 2). Intron F G79A of PZ gene, factor V Leiden (FVL) and prothrombin (PT) G20210A polymorphisms were determined by the method of polymerase chain reaction-based DNA analysis.
RESULTS: The prevalence of FVL was significantly greater in group 1 compared with group 2 (27.3% vs. 3.5%, P < 0.0001). No differences were seen in genotype and allele frequencies of PZ gene between two groups (P > 0.05). When the analysis was also made after excluding FVL positive patients, the same insignificant result was found.
CONCLUSION: Intron F G79A polymorphism of PZ gene does not contribute to meaningful diagnostic investigation of thrombophilia in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246466     DOI: 10.1007/s11239-008-0199-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  10 in total

1.  Identification of novel polymorphisms within the protein Z gene, haplotype distribution and linkage analysis.

Authors:  G I Rice; T S Futers; P J Grant
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

2.  A common polymorphism of the protein Z gene is associated with protein Z plasma levels and with risk of cerebral ischemia in the young.

Authors:  C Lichy; S Kropp; T Dong-Si; J Genius; T Dolan; T Hampe; F Stoll; K Reuner; C Grond-Ginsbach; A Grau
Journal:  Stroke       Date:  2003-12-11       Impact factor: 7.914

3.  Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.

Authors:  Christoph Lichy; Tuan Dong-Si; Karl Reuner; Just Genius; Henning Rickmann; Toni Hampe; Tarah Dolan; Felix Stoll; Armin Grau
Journal:  J Neurol       Date:  2005-09-16       Impact factor: 4.849

4.  Low levels of protein Z and the risk of venous thromboembolism.

Authors:  I Martinelli; C Razzari; E Biguzzi; P Bucciarelli; P M Mannucci
Journal:  J Thromb Haemost       Date:  2005-12       Impact factor: 5.824

5.  Low protein Z levels and risk of occurrence of deep vein thrombosis.

Authors:  R Santacroce; M Sarno; F Cappucci; F Sessa; D Colaizzo; V Brancaccio; E Grandone; M Margaglione
Journal:  J Thromb Haemost       Date:  2006-08-25       Impact factor: 5.824

6.  Protein Z influences the prothrombotic phenotype in Factor V Leiden patients.

Authors:  Bettina Kemkes-Matthes; Margareta Nees; Gitta Kühnel; Axel Matzdorff; Karl J Matthes
Journal:  Thromb Res       Date:  2002-05-15       Impact factor: 3.944

7.  Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk of venous thrombosis.

Authors:  Ali Al-Shanqeeti; Astrid van Hylckama Vlieg; Erik Berntorp; Frits R Rosendaal; George J Broze
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

8.  Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.

Authors:  Aydan Eroglu; Arzu Ulu; Ragip Cam; Cengiz Kurtman; Nejat Akar
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

9.  Protein Z gene polymorphisms, protein Z concentrations, and ischemic stroke.

Authors:  J Staton; M Sayer; G J Hankey; V Cole; J Thom; J W Eikelboom
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

10.  Frequency of protein Z deficiency in patients with ischaemic stroke.

Authors:  M Vasse; E Guegan-Massardier; J Y Borg; F Woimant; C Soria
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

  10 in total
  1 in total

1.  Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer.

Authors:  Ewa Sierko; Marek Z Wojtukiewicz; Lech Zimnoch; Piotr Tokajuk; Krystyna Ostrowska-Cichocka; Walter Kisiel
Journal:  Ann Hematol       Date:  2013-10-26       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.